Trevi Therapeutics Inc
TRVI12.850USD
-0.120-0.93%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
1.65BMarket Cap
LossP/E TTM
More Details of Trevi Therapeutics Inc Company
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. It has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.
Trevi Therapeutics Inc Info
Ticker SymbolTRVI
Company nameTrevi Therapeutics Inc
IPO dateMay 07, 2019
CEOGood (Jennifer L)
Number of employees26
Security typeOrdinary Share
Fiscal year-endMay 07
Address195 Church Street
CityNEW HAVEN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code06510
Phone12033042499
Websitehttps://www.trevitherapeutics.com/
Ticker SymbolTRVI
IPO dateMay 07, 2019
CEOGood (Jennifer L)
Company Executives of Trevi Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. David P. Meeker, M.D.
Dr. David P. Meeker, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
352.49K
--
Dr. Thomas R. Sciascia, M.D.
Dr. Thomas R. Sciascia, M.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
214.43K
--
Ms. Jennifer L. Good
Ms. Jennifer L. Good
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
213.31K
--
Dr. Farrell Simon, Pharm.D.
Dr. Farrell Simon, Pharm.D.
Chief Commercial Officer
Chief Commercial Officer
76.90K
+68.46%
Ms. Anne M. Vanlent
Ms. Anne M. Vanlent
Independent Director
Independent Director
25.98K
--
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Independent Director
Independent Director
6.35K
--
Dr. James V. (Jim) Cassella, Ph.D.
Dr. James V. (Jim) Cassella, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Mr. Dominick C. Colangelo
Mr. Dominick C. Colangelo
Independent Director
Independent Director
--
--
Mr. Edward T. Mathers
Mr. Edward T. Mathers
Independent Director
Independent Director
--
--
Jonathan Carlson
Jonathan Carlson
IR Contact Officer
IR Contact Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. David P. Meeker, M.D.
Dr. David P. Meeker, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
352.49K
--
Dr. Thomas R. Sciascia, M.D.
Dr. Thomas R. Sciascia, M.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
214.43K
--
Ms. Jennifer L. Good
Ms. Jennifer L. Good
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
213.31K
--
Dr. Farrell Simon, Pharm.D.
Dr. Farrell Simon, Pharm.D.
Chief Commercial Officer
Chief Commercial Officer
76.90K
+68.46%
Ms. Anne M. Vanlent
Ms. Anne M. Vanlent
Independent Director
Independent Director
25.98K
--
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Independent Director
Independent Director
6.35K
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
New Enterprise Associates (NEA)
10.31%
Frazier Life Sciences Management, L.P.
8.00%
Rubric Capital Management LP
6.65%
BlackRock Institutional Trust Company, N.A.
5.75%
The Vanguard Group, Inc.
4.53%
Other
64.76%
Shareholders
Shareholders
Proportion
New Enterprise Associates (NEA)
10.31%
Frazier Life Sciences Management, L.P.
8.00%
Rubric Capital Management LP
6.65%
BlackRock Institutional Trust Company, N.A.
5.75%
The Vanguard Group, Inc.
4.53%
Other
64.76%
Shareholder Types
Shareholders
Proportion
Investment Advisor
28.04%
Investment Advisor/Hedge Fund
24.51%
Venture Capital
17.14%
Hedge Fund
16.47%
Private Equity
10.58%
Research Firm
5.74%
Individual Investor
0.76%
Pension Fund
0.37%
Bank and Trust
0.27%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
272
116.14M
95.37%
+14.43M
2025Q2
232
94.28M
77.42%
+5.93M
2025Q1
226
89.66M
76.74%
+2.50M
2024Q4
177
80.67M
91.74%
+11.34M
2024Q3
156
59.14M
78.18%
-6.31M
2024Q2
148
56.93M
80.80%
-4.85M
2024Q1
147
52.57M
76.38%
-8.69M
2023Q4
131
54.54M
85.48%
-544.63K
2023Q3
124
54.64M
88.55%
-1.52M
2023Q2
115
54.75M
93.54%
+3.66M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
New Enterprise Associates (NEA)
11.37M
9.34%
-1.85M
-14.01%
Aug 11, 2025
Frazier Life Sciences Management, L.P.
10.26M
8.42%
--
--
Jun 30, 2025
Rubric Capital Management LP
8.53M
7.01%
+3.99M
+87.99%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.65M
4.64%
+1.10M
+24.11%
Jun 30, 2025
The Vanguard Group, Inc.
5.32M
4.37%
+1.48M
+38.53%
Jun 30, 2025
Vivo Capital, LLC
4.49M
3.69%
+1.00M
+28.67%
Jun 30, 2025
Marshall Wace LLP
2.48M
2.03%
-76.31K
-2.99%
Jun 30, 2025
AllianceBernstein L.P.
4.28M
3.52%
+4.26M
+19064.53%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
State Street SPDR S&P Pharmaceuticals ETF
1.91%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.36%
Invesco Dorsey Wright Healthcare Momentum ETF
1.3%
ALPS Medical Breakthroughs ETF
0.59%
Invesco Dorsey Wright SmallCap Momentum ETF
0.54%
Optimize Strategy Index ETF
0.37%
Vanguard US Momentum Factor ETF
0.22%
iShares Micro-Cap ETF
0.2%
Vanguard US Minimum Volatility ETF
0.18%
ProShares Ultra Nasdaq Biotechnology
0.14%
View more
State Street SPDR S&P Pharmaceuticals ETF
Proportion1.91%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.36%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion1.3%
ALPS Medical Breakthroughs ETF
Proportion0.59%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.54%
Optimize Strategy Index ETF
Proportion0.37%
Vanguard US Momentum Factor ETF
Proportion0.22%
iShares Micro-Cap ETF
Proportion0.2%
Vanguard US Minimum Volatility ETF
Proportion0.18%
ProShares Ultra Nasdaq Biotechnology
Proportion0.14%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Trevi Therapeutics Inc?
The top five shareholders of Trevi Therapeutics Inc are:
New Enterprise Associates (NEA) holds 11.37M shares, accounting for 9.34% of the total shares.
Frazier Life Sciences Management, L.P. holds 10.26M shares, accounting for 8.42% of the total shares.
Rubric Capital Management LP holds 8.53M shares, accounting for 7.01% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 5.65M shares, accounting for 4.64% of the total shares.
The Vanguard Group, Inc. holds 5.32M shares, accounting for 4.37% of the total shares.
New Enterprise Associates (NEA) holds 11.37M shares, accounting for 9.34% of the total shares.
Frazier Life Sciences Management, L.P. holds 10.26M shares, accounting for 8.42% of the total shares.
Rubric Capital Management LP holds 8.53M shares, accounting for 7.01% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 5.65M shares, accounting for 4.64% of the total shares.
The Vanguard Group, Inc. holds 5.32M shares, accounting for 4.37% of the total shares.
What are the top three shareholder types of Trevi Therapeutics Inc?
The top three shareholder types of Trevi Therapeutics Inc are:
New Enterprise Associates (NEA)
Frazier Life Sciences Management, L.P.
Rubric Capital Management LP
New Enterprise Associates (NEA)
Frazier Life Sciences Management, L.P.
Rubric Capital Management LP
How many institutions hold shares of Trevi Therapeutics Inc (TRVI)?
As of 2025Q3, 272 institutions hold shares of Trevi Therapeutics Inc, with a combined market value of approximately 116.14M, accounting for 95.37% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 17.95%.
What is the biggest source of revenue for Trevi Therapeutics Inc?
In --, the -- business generated the highest revenue for Trevi Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
